Intraoperative Radiation Therapy for Breast Cancer: A Valuable but Contested Option

In the rural areas of the South, breast cancer patients often face daunting journeys, sometimes traveling hundreds of miles to access specialized care. Dr. Phillip Ley, a cancer surgeon in Jackson, Mississippi, is one of the practitioners championing a method known as intraoperative radiation therapy (IORT), a single, targeted dose of radiation delivered immediately after tumor removal.

The Benefits of IORT

Dr. Ley underscores the advantages of IORT, particularly for rural patients. This innovative therapy not only minimizes the time spent on treatment—allowing patients to avoid grueling daily radiation sessions—but also significantly reduces costs. “For our patient population here, [IORT] has been such a boon because we have so many rural patients,” Ley noted, highlighting that some patients struggle to afford transportation for traditional radiation treatments.

Financial Implications of IORT

Despite the benefits of IORT, its availability in the U.S. has diminished over the years. Interviews with breast surgeons reveal that financial considerations may underlie this trend, as IORT generates markedly less revenue than traditional radiation options. For example, radiation oncologists are reimbursed approximately $525 for each IORT treatment, while they can earn $1,300 for five sessions of whole breast radiation and $1,730 for 15 sessions.

Clinical Suitability and Safety Concerns

While IORT presents a less taxing alternative, it is not suitable for every patient. Ideal candidates include postmenopausal women with early-stage, small tumors and no lymph node involvement. Despite extensive research indicating that IORT can lead to similar long-term survival rates and lower mortality from other cancers, the American Society for Radiation Oncology (ASTRO) currently does not recommend IORT outside of clinical trials due to its slightly higher recurrence rates.

Dr. Catheryn Yashar, ASTRO’s health policy chair, emphasizes that their stance is based on data rather than financial motives. They aim to provide medical professionals and patients with an objective framework for treatment decisions. “ASTRO’s job is to evaluate the data objectively and give both physicians and patients a framework for decision-making,” she asserts.

Patient Experiences and Insurance Coverage

The experience of patients like Amy Slaton, who opted for IORT despite it not being covered by her employer’s insurance, reflects the ongoing challenges related to access. After paying out-of-pocket, Slaton returned to work within two months—significantly quicker than if she had undergone traditional radiation.

While Medicare and Medicaid do cover IORT, not all private insurance plans follow suit. The discrepancy raises questions regarding the assessment of treatment validity among insurance companies.

A Growing Discrepancy in Treatment Availability

Despite being widely accessible in various international markets for over two decades, IORT faces hurdles in the U.S. Its acceptance and use surged after ASTRO’s first guideline in 2009. However, newer guidelines issued in recent years have dampened its availability, with some surgeons observing a noticeable decline in the option’s presence following the updated recommendations.

Advocacy and Future Directions

Proponents of IORT argue that it represents an effective alternative that shouldn’t be overlooked. Dr. Frederick Barker, a surgeon in Bluefield, Virginia, points out, “the bottom line on this is women… are being denied a valuable option that they’re not being denied in countries other than the U.S.” The financial dynamics at play could deter physicians from readily offering a treatment that has been shown to benefit patients, leading to calls for greater patient advocacy.

Ultimately, IORT offers a valuable option that merits further discussion and support within the healthcare system. As healthcare costs continue to escalate, the potential for savings and the improved quality of life for patients highlights the importance of revisiting treatment avenues such as IORT.